Biotech Innovators Dr. Robert Langer and Brigadier General Larry Lunt Join Sethera Therapeutics Leadership
TL;DR
Dr. Robert Langer's appointment brings unparalleled expertise to Sethera, enhancing its position in peptide therapeutics.
Dr. Langer and Brig. Gen. Lunt join Sethera's leadership team to guide scientific strategy and provide extensive leadership experience.
Sethera's innovative peptide-based therapies hold promise in transforming treatment approaches, impacting global health challenges, and advancing human health.
Dr. Langer's groundbreaking work in drug delivery systems and tissue engineering has led to life-saving therapies, including the COVID-19 vaccine developed by Moderna.
Found this article helpful?
Share it with your network and spread the knowledge!
Sethera Therapeutics has bolstered its leadership team with two distinguished professionals: Dr. Robert Langer, a renowned MIT scientist and Moderna co-founder, and Brigadier General Larry V. Lunt, a seasoned military and business leader.
Dr. Langer, an Institute Professor at MIT with an unprecedented academic record, brings unparalleled expertise in drug delivery systems and tissue engineering. With over 1,500 publications and 443,000 citations, his scientific contributions have been transformative in developing life-saving therapies, including the COVID-19 vaccine.
Brig. Gen. Lunt's appointment complements Langer's scientific prowess with extensive strategic leadership experience. His background in military command and business management provides Sethera with critical organizational insights as the company advances its peptide therapeutics platform.
The strategic additions signal Sethera's commitment to pioneering innovative medical treatments. The company's focus on enzymatically-altered peptides promises potential breakthroughs in therapeutic screening and development across multiple disease areas.
Sethera CEO Karsten Eastman emphasized the significance of these appointments, noting that Langer's expertise and Lunt's organizational understanding will be instrumental in navigating the complex biotechnology landscape.
By recruiting such high-caliber professionals, Sethera positions itself at the forefront of peptide therapeutics, potentially revolutionizing approaches to medical treatment and addressing global health challenges.
Curated from Reportable
